Artivion
AORT
21.26
+0.05
+0.24%
Artivion
US · AORT
#3212 by market cap
21.26
+0.05
+0.24%
Live - 5344 symbols - heartbeat 99s ago
· 2026-10-09 19:30
✦ Quant Financial Health how this is computed
Fair
- Altman Z-Score is 2.29, in the 1.8-3.0 "grey zone".
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +13.59% YoY
Margins
- Gross margin
- 64.40%
- Operating margin
- 6.06%
- Net margin
- 2.21%
Key ratios & quality
- Enterprise valuei
- 1.19B
- Altman Z-Scorei
- 2.29
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 262.84M | 276.22M | 253.23M | 298.84M | 313.79M | 354.00M | 388.54M | 441.33M |
| Gross profit | 172.98M | 183.01M | 167.78M | 197.51M | 202.52M | 229.18M | 248.78M | 284.23M |
| Selling & admin expenses | 140.57M | 143.01M | 141.14M | 169.77M | 157.44M | 208.98M | 181.46M | 226.49M |
| Research & development | 23.10M | 22.96M | 24.21M | 35.55M | 38.88M | 28.71M | 28.45M | 30.99M |
| Operating profit | 9.31M | 17.04M | 2.44M | -7.81M | 6.20M | -8.51M | 38.87M | 26.75M |
| Pretax profit | -6.39M | 1.64M | -17.17M | -14.83M | -14.98M | -21.59M | -7.51M | 14.78M |
| Tax | -3.55M | -76.00K | -492.00K | 7.00K | 4.21M | 9.10M | 5.85M | 5.01M |
| Net profit | -2.84M | 1.72M | -16.68M | -14.83M | -19.19M | -30.69M | -13.36M | 9.77M |
| Basic EPS | 0 | 0 | 0 | 0 | 0 | -1 | 0 | 0 |
| Diluted EPS | -0.08 | 0.05 | -0.44 | -0.38 | -0.48 | -0.75 | -0.32 | 0.21 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 98.98M | 112.97M | 113.39M | 115.99M | 116.34M | 125.76M |
| Gross profit | 63.58M | 73.11M | 74.40M | 73.14M | 75.45M | 80.52M |
| Selling & admin expenses | 54.70M | 57.67M | 57.28M | 56.84M | 60.82M | 79.83M |
| Research & development | 6.73M | 7.06M | 8.08M | 9.12M | 8.84M | 9.06M |
| Operating profit | 2.15M | 8.38M | 9.04M | 7.18M | 5.79M | -8.36M |
| Pretax profit | -2.30M | 3.48M | 7.06M | 6.54M | 339.00K | -11.70M |
| Tax | -1.79M | 2.14M | 554.00K | 4.11M | -1.08M | 1.81M |
| Net profit | -505.00K | 1.35M | 6.50M | 2.43M | 1.42M | -13.51M |
| Basic EPS | 0 | 0 | 0 | 0 | 0 | 0 |
| Diluted EPS | -0.01 | 0.03 | 0.13 | 0.05 | 0.03 | -0.28 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 179.17M | 187.39M | 234.59M | 247.70M | 247.33M | 280.67M | 290.08M | 358.08M |
| Cash & ST investments | 41.49M | 33.77M | 61.41M | 55.01M | 39.35M | 58.94M | 53.46M | 64.91M |
| Inventory | 45.48M | 53.07M | 73.04M | 76.97M | 74.48M | 81.98M | 79.77M | 92.43M |
| Total assets | 571.09M | 605.65M | 789.40M | 793.05M | 762.80M | 792.40M | 789.10M | 884.80M |
| Total current liabilities | 34.52M | 45.20M | 60.47M | 44.95M | 49.68M | 57.86M | 66.82M | 101.56M |
| Short-term debt | 1.89M | 7.25M | 7.57M | 5.31M | 5.43M | 5.43M | 5.29M | 5.38M |
| Long-term debt | 215.72M | 214.57M | 290.47M | 307.49M | 306.50M | 305.53M | 314.15M | 215.11M |
| Total liabilities | 296,024,000.00 | 319,958,000.00 | 460,691,000.00 | 492,324,000.00 | 478,469,000.00 | 510,617,000.00 | 512,901,000.00 | 436,564,000.00 |
| Total equity | 275.07M | 285.70M | 328.71M | 300.73M | 284.33M | 281.78M | 276.20M | 448.23M |
| Retained earnings | 34.98M | 36.70M | 20.02M | 1.98M | -17.22M | -47.91M | -61.27M | -51.50M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 287.30M | 318.82M | 337.50M | 358.08M | 357.52M | 371.38M |
| Cash & ST investments | 37.69M | 53.48M | 73.43M | 64.91M | 55.76M | 77.32M |
| Inventory | 81.93M | 86.72M | 90.55M | 92.43M | 98.00M | 103.36M |
| Total assets | 791.16M | 838.39M | 857.66M | 884.80M | 883.16M | 1.07B |
| Total current liabilities | 51.94M | 66.67M | 85.84M | 101.56M | 92.70M | 106.93M |
| Short-term debt | 5.38M | 5.74M | 5.80M | 5.38M | 5.53M | 5.92M |
| Long-term debt | 314.61M | 215.54M | 214.87M | 215.11M | 215.35M | 363.42M |
| Total liabilities | 496,911,000.00 | 418,485,000.00 | 418,968,000.00 | 436,564,000.00 | 432,690,000.00 | 626,349,000.00 |
| Total equity | 294.25M | 419.90M | 438.69M | 448.23M | 450.47M | 445.59M |
| Retained earnings | -61.77M | -60.43M | -53.92M | -51.50M | -50.08M | -63.59M |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 9.88M | 15.83M | 12.37M | -2.59M | -5.15M | 18.83M | 22.24M | 39.88M |
| Depreciation & amortization | 18.10M | 18.32M | 20.71M | 23.98M | 22.44M | 23.08M | 24.21M | 22.46M |
| Free cash flow | 4.10M | 7.76M | 5.04M | -16.65M | -15.87M | 9.07M | 11.05M | 839.00K |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -2.10M | -2.74M | -2.00M | -1.91M | -1.80M | -559.00K | 0 | 0 |
| Ending cash balance | 42.24M | 34.29M | 61.96M | 55.01M | 39.35M | 58.94M | 53.46M | 64.91M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -16.95M | 15.01M | 22.26M | 19.56M | 1.15M | -1.27M |
| Depreciation & amortization | 5.45M | 5.54M | 5.72M | 5.76M | 6.34M | 6.75M |
| Free cash flow | -20.59M | 11.72M | 17.65M | -7.95M | -6.85M | -12.01M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | -- | -- | -- |
| Ending cash balance | 37.69M | 53.48M | 73.43M | 64.91M | 55.76M | 77.32M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -1.02 | 0.61 | -5.39 | -4.68 | -6.53 | -10.80 | -4.78 | 2.69 |
| ROA %i | -0.48 | 0.29 | -2.38 | -1.86 | -2.45 | -3.93 | -1.69 | 1.17 |
| ROIC %i | 1.71 | 2.94 | -0.10 | -0.37 | -0.74 | -1.78 | 1.97 | 3.99 |
| 5-year avg ROE %i | 2.75 | 1.89 | 0.30 | -1.80 | -3.40 | -5.36 | -6.44 | -4.82 |
| EBIT margin %i | 3.58 | 5.98 | -0.19 | 0.69 | 1.03 | 1.05 | 6.89 | 9.37 |
| FCF / sales %i | 1.56 | 2.81 | 1.99 | -- | -- | 3.22 | 2.84 | 0.19 |
| Current ratioi | 5.19 | 4.15 | 3.88 | 5.51 | 4.98 | 4.85 | 4.34 | 3.53 |
| Quick ratioi | 2.69 | 1.98 | 1.82 | 2.52 | 2.19 | 2.30 | 2.09 | 1.66 |
| Debt / assetsi | 39.14 | 40.48 | 40.20 | 45.65 | 46.78 | 45.22 | 45.91 | 29.12 |
| LT debt / equityi | 80.58 | 83.27 | 94.25 | 118.62 | 123.59 | 125.24 | 129.24 | 56.27 |
| Interest coveragei | 0.60 | 1.11 | -0.03 | 0.12 | 0.18 | 0.15 | 0.78 | 1.56 |
| Revenue CAGR (3Y) %i | 21.68 | 15.26 | 10.11 | 4.37 | 4.34 | 11.81 | 9.14 | 12.04 |
| Net income CAGR (3Y) %i | -- | -45.76 | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -19.85 | -14.24 | 10.25 | -- | -- | 21.64 | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -7.25 | -5.01 | -2.45 | 2.69 | 3.14 | -0.73 |
| ROA %i | -2.71 | -2.20 | -1.10 | 1.17 | 1.39 | -0.33 |
| ROIC %i | 1.49 | 1.12 | 2.13 | 3.99 | 4.02 | 1.40 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 2.95 | 4.05 | 5.31 | 9.37 | 9.09 | 5.62 |
| FCF / sales %i | -- | 1.89 | 4.14 | 0.19 | 3.18 | -- |
| Current ratioi | 5.53 | 4.78 | 3.93 | 3.53 | 3.86 | 3.47 |
| Quick ratioi | 2.57 | 2.32 | 1.99 | 1.66 | 1.74 | 1.76 |
| Debt / assetsi | 45.80 | 31.46 | 30.55 | 29.12 | 29.23 | 38.06 |
| LT debt / equityi | 121.32 | 61.44 | 58.40 | 56.27 | 56.08 | 90.23 |
| Interest coveragei | 0.34 | 0.50 | 0.73 | 1.56 | 1.72 | 1.09 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Single-engine
- Medical devices is the largest reported line at 79.44% of revenue, across 2 reported segments.
- The next-largest line, Preservation services, is a distant second at 20.56% - a sharp slowdown here would have little to offset it.
Revenue breakdown most recent period
Business
Medical devices79.44%
Preservation services20.56%
Quote time 2026-10-09 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Artivion discussion 0 comments